United Therapeutics Stock News

United Therapeutics (UTHR) initiates a second phase III study evaluating its Tyvaso inhalation solution. The study will be conducted in sites outside the United States and Canada.

Tyvaso is being explored by United Therapeutics Corporation in the TETON program (two phase 3 studies) which will determine if label expansion for idiopathic pulmonary fibrosis can be achieved. Tyvaso

August 10, 2022 -- InvestorsHub NewsWire --NetworkNewsWire Editorial Coverage: In medicine, there is a term called "clinical inertia," or the case of what someone doesn't know — or what they ignore — could kill them. Simply put, it means failing to start or intensify a therapy when appropriate, which leads to advanced or chronic disease. It is particularly appropriate with a silent killer such as hypertension, a condition that all too often goes untreated, becoming a culprit in morbidity and mor...

United Therapeutics Corporation (NASDAQ:UTHR ) Q2 2022 Results Conference Call August 3, 2022 9:00 AM ET Company Participants Dewey Steadman - Head, IR Dr. Martine Rothblatt - Chairperson, CEO Michael

United Therapeutics' (UTHR) second-quarter earnings missed estimates, while sales beat the same. Higher sales of Orenitram and Tyvaso drove the top line in the quarter.

United Therapeutics (UTHR) delivered earnings and revenue surprises of -41.22% and 0.85%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its second quarter 2022 financial results before

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Their persistent bullishness -- especially in this rocky environment -- is a testament to their long-term potential.

Biotech stocks have suffered significant setbacks during the first half of the year but are likely to bounce back soon The post 7 Biotech Stocks With Key Catalysts Coming in July appeared first on Inv

It is imperative to build a portfolio of low-beta stocks to sail through a choppy market. United Therapeutics (UTHR), Sanderson (SAFM) and AMN Healthcare (AMN) are well poised to gain.

IMO, PAG and UTHR made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on June 21, 2022.

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced today that James Edgemond, Chief Financial Officer and Treasurer, will prov

The FDA approves United Therapeutics' (UTHR) drug-device combination therapy, Tyvaso DPI, for PAH patients. It is a dry-powder inhalation formulation of Treprostinil.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.